Myelofibrosis: an update on current pharmacotherapy and future directions
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Myelofibrosis: an update on current pharmacotherapy and future directions
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 14, Issue 7, Pages 873-884
Publisher
Informa Healthcare
Online
2013-03-21
DOI
10.1517/14656566.2013.783019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium
- (2012) Omar Abdel-Wahab et al. AMERICAN JOURNAL OF HEMATOLOGY
- The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
- (2012) B. L. Scott et al. BLOOD
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
- (2012) T. L. Lasho et al. BLOOD
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- Mutation analysis ofASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12,andTET2in myeloproliferative neoplasms
- (2012) Mandy Brecqueville et al. GENES CHROMOSOMES & CANCER
- Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis
- (2012) M. Ditschkowski et al. HAEMATOLOGICA
- Improving Survival Trends in Primary Myelofibrosis: An International Study
- (2012) Francisco Cervantes et al. JOURNAL OF CLINICAL ONCOLOGY
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- EZH2 mutational status predicts poor survival in myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- Recombinant interferon- may retard progression of early primary myelofibrosis: a preliminary report
- (2011) R. T. Silver et al. BLOOD
- European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis
- (2011) T. Buhr et al. HAEMATOLOGICA
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
- (2010) Alejandra Martínez-Trillos et al. ANNALS OF HEMATOLOGY
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
- (2010) R. A. Mesa et al. BLOOD
- JAK2 inhibitors: What's the true therapeutic potential?
- (2010) Fabio P.S. Santos et al. BLOOD REVIEWS
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis
- (2010) Haefaa Alchalby et al. Current Hematologic Malignancy Reports
- Outcome of Transplantation for Myelofibrosis
- (2009) Karen K. Ballen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2009) N. Kroger et al. BLOOD
- Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
- (2009) F. P. S. Santos et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
- (2008) C. S. Tam et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started